Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

UroGen Pharma (URGN) FCF Margin (2018 - 2025)

UroGen Pharma's FCF Margin history spans 8 years, with the latest figure at 101.33% for Q4 2025.

  • For Q4 2025, FCF Margin fell 4543.0% year-over-year to 101.33%; the TTM value through Dec 2025 reached 148.22%, down 4085.0%, while the annual FY2025 figure was 148.22%, 4085.0% down from the prior year.
  • FCF Margin reached 101.33% in Q4 2025 per URGN's latest filing, up from 154.13% in the prior quarter.
  • In the past five years, FCF Margin ranged from a high of 55.47% in Q4 2023 to a low of 369.91% in Q1 2021.
  • Average FCF Margin over 5 years is 140.85%, with a median of 135.62% recorded in 2021.
  • Peak YoY movement for FCF Margin: surged 636378bps in 2021, then crashed -5597bps in 2025.
  • A 5-year view of FCF Margin shows it stood at 125.34% in 2021, then increased by 4bps to 120.3% in 2022, then surged by 54bps to 55.47% in 2023, then dropped by -1bps to 55.91% in 2024, then tumbled by -81bps to 101.33% in 2025.
  • Per Business Quant, the three most recent readings for URGN's FCF Margin are 101.33% (Q4 2025), 154.13% (Q3 2025), and 165.05% (Q2 2025).